Palomar Holdings, Inc. (NASDAQ:PLMR – Get Free Report) President Jon Christianson sold 3,000 shares of the stock in a transaction on Monday, July 20th. The shares were sold at an average price of $139.50, for a total value of $418,500.00. Following the transaction, the president directly owned 66,478 shares in the company, valued at $9,273,681. The trade was a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jon Christianson also recently made the following trade(s):
- On Thursday, July 2nd, Jon Christianson sold 6,863 shares of Palomar stock. The stock was sold at an average price of $139.50, for a total value of $957,388.50.
Palomar Stock Performance
Shares of PLMR opened at $136.30 on Friday. The firm has a market capitalization of $3.61 billion, a P/E ratio of 18.98 and a beta of 0.41. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.49 and a quick ratio of 0.49. Palomar Holdings, Inc. has a one year low of $100.81 and a one year high of $147.62. The business has a fifty day moving average of $123.91 and a 200 day moving average of $123.45.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on PLMR shares. Evercore set a $152.00 price objective on shares of Palomar in a report on Friday, July 10th. Zacks Research cut shares of Palomar from a “strong-buy” rating to a “hold” rating in a report on Friday, May 15th. Weiss Ratings upgraded shares of Palomar from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 18th. Keefe, Bruyette & Woods lifted their price target on shares of Palomar from $162.00 to $166.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 8th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Palomar from $150.00 to $167.00 and gave the company an “overweight” rating in a research report on Monday, July 20th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Palomar currently has an average rating of “Moderate Buy” and a consensus price target of $162.50.
View Our Latest Research Report on Palomar
Institutional Investors Weigh In On Palomar
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Palomar by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 2,698,278 shares of the company’s stock worth $363,620,000 after purchasing an additional 67,038 shares during the period. Janus Henderson Group PLC raised its position in shares of Palomar by 17.4% during the 1st quarter. Janus Henderson Group PLC now owns 933,993 shares of the company’s stock valued at $111,664,000 after purchasing an additional 138,368 shares during the period. Westfield Capital Management Co. LP raised its position in shares of Palomar by 13.8% during the 4th quarter. Westfield Capital Management Co. LP now owns 840,226 shares of the company’s stock valued at $113,229,000 after purchasing an additional 101,698 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Palomar by 72.1% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 785,165 shares of the company’s stock valued at $105,809,000 after buying an additional 328,993 shares in the last quarter. Finally, Stephens Investment Management Group LLC lifted its stake in shares of Palomar by 3.0% during the 1st quarter. Stephens Investment Management Group LLC now owns 714,914 shares of the company’s stock valued at $85,432,000 after buying an additional 20,597 shares in the last quarter. Institutional investors own 90.25% of the company’s stock.
Palomar Company Profile
Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.
In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.
Read More
- Five stocks we like better than Palomar
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Palomar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palomar and related companies with MarketBeat.com's FREE daily email newsletter.
